Chong Kun Dang Signs 160 Billion KRW Contract to Adopt Synaffix ADC Platform Technology
![Jongkundang exterior. [Photo by Jongkundang]](http://www.asiae.co.kr/news/img_view.htm?img=2020062209152017689_1592784920.jpg)
[Asia Economy Reporter Lee Gwan-ju] Chong Kun Dang announced on the 3rd that it has signed an ADC platform technology licensing agreement with Synaffix, a Netherlands-based antibody-drug conjugate (ADC) specialist company.
The total contract amount, including the signing fee and milestones, is $132 million (approximately 160 billion KRW), but detailed information will be withheld until the payment date at Synaffix's request.
Chong Kun Dang plans to apply Synaffix's ADC platform technology to its internally developed antibodies for ADC development.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- "Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Sold Out Everywhere" The Surprising Story of the 'Purple Gold' Philippine Yam That Has Captivated the World [Delicious Stories]
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
ADC is a technology that links antibodies, which bind only to specific antigens, with highly effective chemotherapeutic drugs, enabling the drugs to selectively target cancer cells expressing the antigen. It has recently attracted attention as the next-generation growth engine in the pharmaceutical and biotech industries.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
